A Phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, everolimus, in patients with recurrent endometrial carcinoma

BACKGROUND: Dysregulation of PTEN and PIK3CA are the most common mutations in endometrial cancer (EC). Loss of PTEN or activation of PIK3CA results in constitutive activation of AKT, which leads to up-regulation of mTOR. Everolimus is an oral rapamycin analog that acts by selectively inhibiting mTOR...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Slomovitz, Brian M., Lu, Karen H., Johnston, Taren, Coleman, Robert L., Munsell, Mark, Broaddus, Russell R., Walker, Cheryl, Ramondetta, Lois M., Burke, Thomas W., Gershenson, David M., Wolf, Judith
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5120730/
https://ncbi.nlm.nih.gov/pubmed/20681032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25515
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados